Inflammatory Breast Cancer — Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
Citation(s)
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.